Arcus Biosciences Inc. (RCUS.N): Takeaways from Cas investor event

RCUS held an investor event on Oct 20 to review the emerging profile of key pipeline asset casdatifan (Cas; HIF-2α inhibitor) and the ongoing development program for kidney cancer across lines of therapy, presenting updated data in first-line, second-line and late-line metastatic clear cell RCC. Management discussed the potential for Cas to serve as a backbone therapy across all lines of ccRCC, noting >300 patients have now been treated with Cas across cohorts in the ARC-20 Ph1/2 study. Late-line monotherapy (n=121) showed mOS of 34.7 months, mPFS of 13.0 months and cORR of 36%, comparing favorably to Welireg's 21.4-month mOS in LITESPARK-005 on a cross-trial basis. Cas+cabo in 2L (n=44) showed mPFS of ~14.5 months and cORR of 44%, in line with Welireg+Lenvima. Management reiterated expectations to complete enrollment in the Ph3 PEAK-1 study (Cas+cabo vs. cabo in I/O-experienced ccRCC) over the next few months with data expected in 1H28, and plans to initiate the Ph3 PEAK-20 study (Cas